Latest Doxorubicin Stories
Younger lymphoma patients given a more intensive chemotherapy regimen combined with rituximab live much longer, and are more than twice as likely to remain in remission 4 years later, compared to patients given standard chemo.
The future looks bright for patients with HER2-positive breast cancer. A paper published in the October 6, 2011 issue of the New England Journal of Medicine (NEJM), shows that new treatment regimens, providing a lower risk of cardio toxicity, are an acceptable and effective option for patients.
- To swell, as grain or wood with water.